Opus Genetics (IRD) Total Current Liabilities (2018 - 2026)

Opus Genetics (IRD) has 9 years of Total Current Liabilities data on file, last reported at $9.3 million in Q1 2026.

• Quarterly Total Current Liabilities fell 61.49% year-over-year to $9.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.3 million (down 61.49% YoY) and the FY2025 annual result came in at $7.8 million, down 31.11% from the prior year.
• Total Current Liabilities improved to $9.3 million in Q1 2026 per IRD's latest filing, from $7.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $29.1 million in Q3 2025 and bottomed at $2.7 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $5.8 million (2023), against an average of $8.7 million.
• The widest annual swing landed in 2025, when Total Current Liabilities soared 380.99%; it then sank 61.49% in 2026.
• Tracing IRD's Total Current Liabilities over 5 years: stood at $2.8 million in 2022, then soared by 46.82% to $4.0 million in 2023, then soared by 179.44% to $11.3 million in 2024, then plunged by 31.11% to $7.8 million in 2025, then gained by 20.04% to $9.3 million in 2026.
• Per Business Quant, the three latest IRD Total Current Liabilities figures stand at $9.3 million (Q1 2026), $7.8 million (Q4 2025), and $29.1 million (Q3 2025).

Peer Comparison